2022 Fiscal Year Final Research Report
Novel Therapeutic Strategies with Pin1 Inhibition in Ovarian Cancer
| Project/Area Number |
20K09661
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小暮 佳代子 群馬大学, 大学院医学系研究科, 助教 (00782319)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 卵巣癌 / Pin1 / ドラッグリポジショニング |
|---|
| Outline of Final Research Achievements |
Pin1 is expressed in ovarian cancer tissue, with higher expression in serous carcinomas and tumors with extra-ovarian lesions, and Pin1 expression is an independent prognostic factor in non-serous carcinomas. Inhibition of Pin1 function in cultured cells exerts an antitumor effect, making Pin1 inhibition a potential therapeutic target for ovarian cancer. Candidate drugs were screened in cultured cells to evaluate the possibility of low-dose inhibition by drug disposition, but no effective combinations were detected.
To explore the mechanism of the anti-tumor effect of Pin1, the expression of Pin1-related proteins in tumor tissues was evaluated by immunostaining, but no relevant proteins associated with Pin1 expression were detected.
|
| Free Research Field |
婦人科腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
プラチナ抵抗性再発卵巣癌に対する薬物療法は抗がん剤±血管新生阻害剤の組み合わせが標準治療であるが効果が限定的であることに加え、特有の有害事象や医療経済への圧迫が課題である。抗腫瘍効果を持ちつつ有害反応が少ない薬物療法の選択肢があれば、患者のニーズに合致するものと思われる。近年、既存薬を別疾患の治療に流用することで、薬剤開発の経費削減や安全性検証のステップを簡略化するドラッグ・リポジショニングが積極的に進められている。本研究では本領域においてPin1阻害剤と他の薬剤を併用することで卵巣癌治療への新規治療戦略を確立することを目指したが、有効な組み合わせは見出されなかった。
|
